Trials / Completed
CompletedNCT02377752
A Study of Olaratumab in Japanese Participants With Advanced Cancer
A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \[STS\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Olaratumab | Administered IV |
| DRUG | Doxorubicin | Administered IV |
Timeline
- Start date
- 2015-03-23
- Primary completion
- 2018-08-27
- Completion
- 2020-01-14
- First posted
- 2015-03-04
- Last updated
- 2021-02-17
- Results posted
- 2021-02-17
Locations
4 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02377752. Inclusion in this directory is not an endorsement.